Fight the Fakes gathers manufacturers and other stakeholders to brainstorm on ways to combat falsified medicines and safeguard the world’s medicine supply.
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
A new survey from the supply-chain analysis company revals inefficiencies, inaccurate data and other flaws can be costly in terms of revenue, reputation and patient lives.
According to an executive from the drug development services company, pharma professionals should pay close attention to supply chain continuity and safety in the coming year.
A representative from the small-molecule solutions company explains how the ever-increasing mountain of life-sciences data has impacted drug development.
Sanofi has made a new five-year, $25m partnership agreement with the World Health Organization (WHO) to fight Neglected Topical Diseases (NTD); and eliminate sleeping sickness by 2030.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
The pharma ingredients provider discusses new products, supply-chain obstacles, and what the future of the industry might hold, ahead of the online event.
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
An executive from Pharmaceutical Associates Inc. believes bringing drug manufacturing back to the country will help avoid shortages and other disasters.
The bipartisan bill calls for an assessment of the country’s pharma supply chain, including potential vulnerabilities and impact of foreign manufacturing.
The imaging company’s newly launched division, created to produce drug ingredients, received the loan from the US International Development Finance Corp.
The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
The two firms are joining forces to develop AI-based technology for continuous manufacturing of critical APIs necessary for producing crucial small-molecule drugs.
After the Indian government moved to limit the export of APIs, an Indian export association says fear is spreading amongst European businesses over supply.
With the supply of certain APIs limited by the spread of the virus, Indian government orders restrictions on the export of ingredients and formulations.
